Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors

NCT04861987 is registered in ClinicalTrials.gov with Processa Pharmaceuticals as lead sponsor.

NCT NCT04861987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04861987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors
Lead sponsor
Processa Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2021
Completion date
September 9, 2024
Enrollment
23 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, refractory cancer, tumor gastric